Clinical Trial Update: The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial. [Phase 3]

View source ↗

Summary

A Phase 3 pragmatic multicenter randomized trial investigating whether time-of-day dependent administration of nivolumab-ipilimumab improves overall survival in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Guliz Ozgun | Conditions: Advanced Kidney Cancer | Phase 3 | Status: NOT_YET_RECRUITING